ChloroquineV1, Istex, Corpus, bibRecord, 000917

EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS

Identifieur interne : 000917 ( Istex/Corpus ); précédent : 000916; suivant : 000918

EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS

Auteurs : C. Bologna ; P. Viu ; C. Jorgensen ; J. Sany

Source :

Rheumatology [ 1462-0324 ] ; 1996.

RBID : ISTEX:1780ED1EA69EA4451EAB1316322600274B78E03C

Abstract

The objective of this study was to assess the influence of age on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Four hundred and sixty-nine patients were separated according to the age of onset of methotrexate treatment; before 65 yr (group l, n = 416) and after 65 yr (group 2, n = 53). No difference was found in the evolution of clinical and biological parameters between the two groups. The number of patients in remission at the end of the study was equal. The frequency and type of side-effects were similar. No significant difference was found in the frequency and reasons for methotrexate withdrawal. We noted a trend towards lower therapeutic maintenance of methotrexate when prescribed after the age of 65 yr (P = 0.07, actuarial method). In conclusion, the age at initiation of methotrexate treatment probably did not influence its efficacy and toxicity in rheumatoid arthritis.

Url:

https://api.istex.fr/ark:/67375/HXZ-1RTQJKZN-Z/fulltext.pdf

DOI: 10.1093/rheumatology/35.5.453

Links to Exploration step

ISTEX:1780ED1EA69EA4451EAB1316322600274B78E03C

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS</title>
<author><name sortKey="Bologna, C" sort="Bologna, C" uniqKey="Bologna C" first="C." last="Bologna">C. Bologna</name>
<affiliation><mods:affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Viu, P" sort="Viu, P" uniqKey="Viu P" first="P." last="Viu">P. Viu</name>
<affiliation><mods:affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Jorgensen, C" sort="Jorgensen, C" uniqKey="Jorgensen C" first="C." last="Jorgensen">C. Jorgensen</name>
<affiliation><mods:affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sany, J" sort="Sany, J" uniqKey="Sany J" first="J." last="Sany">J. Sany</name>
<affiliation><mods:affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Correspondence to: J. Sany, Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, 34295 Montpellier Cedex 5, France.</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1780ED1EA69EA4451EAB1316322600274B78E03C</idno>
<date when="1996" year="1996">1996</date>
<idno type="doi">10.1093/rheumatology/35.5.453</idno>
<idno type="url">https://api.istex.fr/ark:/67375/HXZ-1RTQJKZN-Z/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000917</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000917</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS</title>
<author><name sortKey="Bologna, C" sort="Bologna, C" uniqKey="Bologna C" first="C." last="Bologna">C. Bologna</name>
<affiliation><mods:affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Viu, P" sort="Viu, P" uniqKey="Viu P" first="P." last="Viu">P. Viu</name>
<affiliation><mods:affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Jorgensen, C" sort="Jorgensen, C" uniqKey="Jorgensen C" first="C." last="Jorgensen">C. Jorgensen</name>
<affiliation><mods:affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sany, J" sort="Sany, J" uniqKey="Sany J" first="J." last="Sany">J. Sany</name>
<affiliation><mods:affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Correspondence to: J. Sany, Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, 34295 Montpellier Cedex 5, France.</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Rheumatology</title>
<idno type="eISSN">1462-0332</idno>
<idno type="ISSN">1462-0324</idno>
<imprint><publisher>Oxford University Press</publisher>
<date when="1996-05">1996</date>
<biblScope unit="vol">35</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="453">453</biblScope>
<biblScope unit="page" to="457">457</biblScope>
</imprint>
<idno type="ISSN">1462-0324</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1462-0324</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">The objective of this study was to assess the influence of age on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Four hundred and sixty-nine patients were separated according to the age of onset of methotrexate treatment; before 65 yr (group l, n = 416) and after 65 yr (group 2, n = 53). No difference was found in the evolution of clinical and biological parameters between the two groups. The number of patients in remission at the end of the study was equal. The frequency and type of side-effects were similar. No significant difference was found in the frequency and reasons for methotrexate withdrawal. We noted a trend towards lower therapeutic maintenance of methotrexate when prescribed after the age of 65 yr (P = 0.07, actuarial method). In conclusion, the age at initiation of methotrexate treatment probably did not influence its efficacy and toxicity in rheumatoid arthritis.</div>
</front>
</TEI>
<istex><corpusName>oup</corpusName>
<author><json:item><name>C. BOLOGNA</name>
<affiliations><json:string>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</json:string>
</affiliations>
</json:item>
<json:item><name>P. VIU</name>
<affiliations><json:string>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</json:string>
</affiliations>
</json:item>
<json:item><name>C. JORGENSEN</name>
<affiliations><json:string>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</json:string>
</affiliations>
</json:item>
<json:item><name>J. SANY</name>
<affiliations><json:string>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</json:string>
<json:string>Correspondence to: J. Sany, Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, 34295 Montpellier Cedex 5, France.</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><value>Methotrexate</value>
</json:item>
<json:item><value>Age</value>
</json:item>
<json:item><value>Efficacy</value>
</json:item>
<json:item><value>Tolerance</value>
</json:item>
<json:item><value>Rheumatoid arthritis</value>
</json:item>
</subject>
<articleId><json:string>35.5.453</json:string>
</articleId>
<arkIstex>ark:/67375/HXZ-1RTQJKZN-Z</arkIstex>
<language><json:string>unknown</json:string>
</language>
<originalGenre><json:string>other</json:string>
</originalGenre>
<abstract>The objective of this study was to assess the influence of age on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Four hundred and sixty-nine patients were separated according to the age of onset of methotrexate treatment; before 65 yr (group l, n = 416) and after 65 yr (group 2, n = 53). No difference was found in the evolution of clinical and biological parameters between the two groups. The number of patients in remission at the end of the study was equal. The frequency and type of side-effects were similar. No significant difference was found in the frequency and reasons for methotrexate withdrawal. We noted a trend towards lower therapeutic maintenance of methotrexate when prescribed after the age of 65 yr (P = 0.07, actuarial method). In conclusion, the age at initiation of methotrexate treatment probably did not influence its efficacy and toxicity in rheumatoid arthritis.</abstract>
<qualityIndicators><score>5.399</score>
<pdfWordCount>3611</pdfWordCount>
<pdfCharCount>22257</pdfCharCount>
<pdfVersion>1.2</pdfVersion>
<pdfPageCount>5</pdfPageCount>
<pdfPageSize>622 x 804 pts</pdfPageSize>
<pdfWordsPerPage>722</pdfWordsPerPage>
<pdfText>true</pdfText>
<refBibsNative>false</refBibsNative>
<abstractWordCount>149</abstractWordCount>
<abstractCharCount>910</abstractCharCount>
<keywordCount>5</keywordCount>
</qualityIndicators>
<title>EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS</title>
<pmid><json:string>8646436</json:string>
</pmid>
<genre><json:string>other</json:string>
</genre>
<host><title>Rheumatology</title>
<language><json:string>unknown</json:string>
</language>
<issn><json:string>1462-0324</json:string>
</issn>
<eissn><json:string>1462-0332</json:string>
</eissn>
<publisherId><json:string>brheum</json:string>
</publisherId>
<volume>35</volume>
<issue>5</issue>
<pages><first>453</first>
<last>457</last>
</pages>
<genre><json:string>journal</json:string>
</genre>
<subject><json:item><value>Clinical Papers</value>
</json:item>
</subject>
</host>
<namedEntities><unitex><date><json:string>1996</json:string>
</date>
<geogName></geogName>
<orgName><json:string>Society for Rheumatology</json:string>
<json:string>ACR</json:string>
<json:string>American College of Rheumatology</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>Wolfe</json:string>
<json:string>J. Sany</json:string>
<json:string>Cathey</json:string>
</persName>
<placeName><json:string>Montpellier</json:string>
<json:string>Toxicity</json:string>
<json:string>BOLOGNA</json:string>
<json:string>France</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl><json:string>[12, 13]</json:string>
<json:string>[3-6]</json:string>
<json:string>[11]</json:string>
<json:string>[8]</json:string>
<json:string>[17]</json:string>
<json:string>[21]</json:string>
<json:string>[16]</json:string>
<json:string>[20]</json:string>
<json:string>[15, 19]</json:string>
<json:string>Buchbinder et al. [15]</json:string>
<json:string>[1-6]</json:string>
<json:string>[7]</json:string>
<json:string>[14, 16]</json:string>
<json:string>[14]</json:string>
<json:string>[14-16]</json:string>
<json:string>[9]</json:string>
<json:string>[1,2]</json:string>
<json:string>Kaye et al. [18]</json:string>
<json:string>[19]</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/HXZ-1RTQJKZN-Z</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - rheumatology</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - arthritis & rheumatology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Pharmacology (medical)</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Rheumatology</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
</inist>
</categories>
<publicationDate>1996</publicationDate>
<copyrightDate>1996</copyrightDate>
<doi><json:string>10.1093/rheumatology/35.5.453</json:string>
</doi>
<id>1780ED1EA69EA4451EAB1316322600274B78E03C</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1RTQJKZN-Z/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1RTQJKZN-Z/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-1RTQJKZN-Z/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS</title>
<respStmt><resp>Références bibliographiques récupérées via GROBID</resp>
<name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name>
</respStmt>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Oxford University Press</publisher>
<availability><licence>© 1996 British Society for Rheumatology</licence>
</availability>
<date type="Copyright" when="1996">1996</date>
<date when="1996-05">1996</date>
</publicationStmt>
<notesStmt><note type="content-type" source="other" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="other"><analytic><title level="a" type="main" xml:lang="en">EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS</title>
<author xml:id="author-0000"><persName><surname>BOLOGNA</surname>
<forename type="first">C.</forename>
</persName>
<affiliation><orgName type="laboratory">Service d'Immuno-Rhumatologie</orgName>
<address><addrLine>CHU Gui-de-Chauliac, Montpellier, France</addrLine>
</address>
</affiliation>
</author>
<author xml:id="author-0001"><persName><surname>VIU</surname>
<forename type="first">P.</forename>
</persName>
<affiliation><orgName type="laboratory">Service d'Immuno-Rhumatologie</orgName>
<address><addrLine>CHU Gui-de-Chauliac, Montpellier, France</addrLine>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><surname>JORGENSEN</surname>
<forename type="first">C.</forename>
</persName>
<affiliation><orgName type="laboratory">Service d'Immuno-Rhumatologie</orgName>
<address><addrLine>CHU Gui-de-Chauliac, Montpellier, France</addrLine>
</address>
</affiliation>
</author>
<author xml:id="author-0003"><persName><surname>SANY</surname>
<forename type="first">J.</forename>
</persName>
<affiliation><orgName type="laboratory">Service d'Immuno-Rhumatologie</orgName>
<address><addrLine>CHU Gui-de-Chauliac, Montpellier, France</addrLine>
</address>
</affiliation>
<affiliation role="corresp">Correspondence to: J. Sany, Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, 34295 Montpellier Cedex 5, France.</affiliation>
</author>
<idno type="istex">1780ED1EA69EA4451EAB1316322600274B78E03C</idno>
<idno type="ark">ark:/67375/HXZ-1RTQJKZN-Z</idno>
<idno type="publisher-id">35.5.453</idno>
<idno type="DOI">10.1093/rheumatology/35.5.453</idno>
</analytic>
<monogr><title level="j" type="main">Rheumatology</title>
<idno type="hwp">rheumatology</idno>
<idno type="publisher-id">brheum</idno>
<idno type="pmc">rheumatology</idno>
<idno type="eISSN">1462-0332</idno>
<idno type="pISSN">1462-0324</idno>
<imprint><publisher>Oxford University Press</publisher>
<date when="1996-05">1996</date>
<biblScope unit="vol">35</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="453">453</biblScope>
<biblScope unit="page" to="457">457</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-09"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
                        <ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><abstract><p>The objective of this study was to assess the influence of age on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Four hundred and sixty-nine patients were separated according to the age of onset of methotrexate treatment; before 65 yr (group l, <hi rend="italic">n</hi>
 = 416) and after 65 yr (group 2, <hi rend="italic">n</hi>
 = 53). No difference was found in the evolution of clinical and biological parameters between the two groups. The number of patients in remission at the end of the study was equal. The frequency and type of side-effects were similar. No significant difference was found in the frequency and reasons for methotrexate withdrawal. We noted a trend towards lower therapeutic maintenance of methotrexate when prescribed after the age of 65 yr (<hi rend="italic">P</hi>
 = 0.07, actuarial method). In conclusion, the age at initiation of methotrexate treatment probably did not influence its efficacy and toxicity in rheumatoid arthritis.</p>
</abstract>
<textClass ana="subject"><keywords scheme="subject"><term>Clinical Papers</term>
</keywords>
</textClass>
<textClass ana="keyword"><keywords><term>Methotrexate</term>
<term>Age</term>
<term>Efficacy</term>
<term>Tolerance</term>
<term>Rheumatoid arthritis</term>
</keywords>
</textClass>
<langUsage><language ident="EN"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2019-12-09" who="#istex" xml:id="pub2tei">formatting</change>
<change xml:id="refBibs-istex" who="#ISTEX-API" when="2019-12-12">References added</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1RTQJKZN-Z/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType>
<istex:document><article article-type="other">

<front>

<journal-meta>

<journal-id journal-id-type="hwp">rheumatology</journal-id>

<journal-id journal-id-type="publisher-id">brheum</journal-id>

<journal-id journal-id-type="pmc">rheumatology</journal-id>

<journal-title>Rheumatology</journal-title>

<issn pub-type="epub">1462-0332</issn>

<issn pub-type="ppub">1462-0324</issn>

<publisher>

<publisher-name>Oxford University Press</publisher-name>

</publisher>

</journal-meta>

<article-meta>

<article-id pub-id-type="publisher-id">35.5.453</article-id>

<article-id pub-id-type="doi">10.1093/rheumatology/35.5.453</article-id>

<article-categories>

<subj-group>

<subject>Clinical Papers</subject>

</subj-group>

</article-categories>

<title-group>

<article-title>EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS</article-title>

</title-group>

<contrib-group>

<contrib contrib-type="author">

<name><surname>BOLOGNA</surname>
<given-names>C.</given-names>
</name>

</contrib>

<contrib contrib-type="author">

<name><surname>VIU</surname>
<given-names>P.</given-names>
</name>

</contrib>

<contrib contrib-type="author">

<name><surname>JORGENSEN</surname>
<given-names>C.</given-names>
</name>

</contrib>

<contrib contrib-type="author">

<name><surname>SANY</surname>
<given-names>J.</given-names>
</name>
<xref ref-type="corresp" rid="cor1"></xref>

</contrib>

<aff><institution>Service d'Immuno-Rhumatologie</institution>
 <addr-line>CHU Gui-de-Chauliac, Montpellier, France</addr-line>
</aff>

</contrib-group>

<author-notes>

<corresp id="cor1">Correspondence to: J. Sany, Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, 34295 Montpellier Cedex 5, France.</corresp>

</author-notes>

<pub-date pub-type="ppub">

<month>5</month>

<year>1996</year>

</pub-date>

<volume>35</volume>

<issue>5</issue>

<fpage>453</fpage>

<lpage>457</lpage>

<history>

<date date-type="received">

<day>25</day>

<month>7</month>

<year>1995</year>

</date>

<date date-type="accepted">

<day>07</day>

<month>11</month>

<year>1995</year>

</date>

</history>

<copyright-statement>© 1996 British Society for Rheumatology</copyright-statement>

<copyright-year>1996</copyright-year>

<abstract>

<p>The objective of this study was to assess the influence of age on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Four hundred and sixty-nine patients were separated according to the age of onset of methotrexate treatment; before 65 yr (group l, <italic>n</italic>
 = 416) and after 65 yr (group 2, <italic>n</italic>
 = 53). No difference was found in the evolution of clinical and biological parameters between the two groups. The number of patients in remission at the end of the study was equal. The frequency and type of side-effects were similar. No significant difference was found in the frequency and reasons for methotrexate withdrawal. We noted a trend towards lower therapeutic maintenance of methotrexate when prescribed after the age of 65 yr (<italic>P</italic>
 = 0.07, actuarial method). In conclusion, the age at initiation of methotrexate treatment probably did not influence its efficacy and toxicity in rheumatoid arthritis.</p>

</abstract>

<kwd-group>

<kwd>Methotrexate</kwd>

<kwd>Age</kwd>

<kwd>Efficacy</kwd>

<kwd>Tolerance</kwd>

<kwd>Rheumatoid arthritis</kwd>

</kwd-group>

</article-meta>

</front>

</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo><title>EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA"><title>EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS</title>
</titleInfo>
<name type="personal"><namePart type="given">C.</namePart>
<namePart type="family">BOLOGNA</namePart>
<affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">P.</namePart>
<namePart type="family">VIU</namePart>
<affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">C.</namePart>
<namePart type="family">JORGENSEN</namePart>
<affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J.</namePart>
<namePart type="family">SANY</namePart>
<affiliation>Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, Montpellier, France</affiliation>
<affiliation>Correspondence to: J. Sany, Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, 34295 Montpellier Cedex 5, France.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="other" displayLabel="other" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</genre>
<originInfo><publisher>Oxford University Press</publisher>
<dateIssued encoding="w3cdtf">1996-05</dateIssued>
<dateCreated encoding="w3cdtf">1995-11-07</dateCreated>
<copyrightDate encoding="w3cdtf">1996</copyrightDate>
</originInfo>
<abstract>The objective of this study was to assess the influence of age on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Four hundred and sixty-nine patients were separated according to the age of onset of methotrexate treatment; before 65 yr (group l, n = 416) and after 65 yr (group 2, n = 53). No difference was found in the evolution of clinical and biological parameters between the two groups. The number of patients in remission at the end of the study was equal. The frequency and type of side-effects were similar. No significant difference was found in the frequency and reasons for methotrexate withdrawal. We noted a trend towards lower therapeutic maintenance of methotrexate when prescribed after the age of 65 yr (P = 0.07, actuarial method). In conclusion, the age at initiation of methotrexate treatment probably did not influence its efficacy and toxicity in rheumatoid arthritis.</abstract>
<note type="author-notes">Correspondence to: J. Sany, Service d'Immuno-Rhumatologie, CHU Gui-de-Chauliac, 34295 Montpellier Cedex 5, France.</note>
<subject><genre>keywords</genre>
<topic>Methotrexate</topic>
<topic>Age</topic>
<topic>Efficacy</topic>
<topic>Tolerance</topic>
<topic>Rheumatoid arthritis</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Rheumatology</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<subject><topic>Clinical Papers</topic>
</subject>
<identifier type="ISSN">1462-0324</identifier>
<identifier type="eISSN">1462-0332</identifier>
<identifier type="PublisherID">brheum</identifier>
<identifier type="PublisherID-hwp">rheumatology</identifier>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>35</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>5</number>
</detail>
<extent unit="pages"><start>453</start>
<end>457</end>
</extent>
</part>
</relatedItem>
<identifier type="istex">1780ED1EA69EA4451EAB1316322600274B78E03C</identifier>
<identifier type="ark">ark:/67375/HXZ-1RTQJKZN-Z</identifier>
<identifier type="DOI">10.1093/rheumatology/35.5.453</identifier>
<identifier type="ArticleID">35.5.453</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© 1996 British Society for Rheumatology</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource>
<recordOrigin>Converted from  (version 1.2.0) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2019-12-09</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1RTQJKZN-Z/record.json</uri>
</json:item>
</metadata>
<annexes><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-1RTQJKZN-Z/annexes.pdf</uri>
</json:item>
</annexes>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000917 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000917 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:1780ED1EA69EA4451EAB1316322600274B78E03C
   |texte=   EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS

EFFECT OF AGE ON THE EFFICACY AND TOLERANCE OF METHOTREXATE IN RHEUMATOID ARTHRITIS

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri